We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

By LabMedica International staff writers
Posted on 13 Jun 2025

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. More...

A Knowledge Transfer Partnership (KTP) between Aston University (Birmingham, UK) and BG Research (Kimbolton, UK) will help to further develop technology to rapidly diagnose serious and high-risk infectious diseases. CENOS, developed by BG Research, uses a portable and robust instrument that can deliver fast RT-PCR (Real Time Polymerase Chain Reaction) tests directly from unprocessed samples of blood, swab, saliva, or urine.

The platform is designed for use in remote locations, as it does not require specialist personnel or laboratory equipment and can be easily scaled in the event of an outbreak. PCR tests, used during the COVID-19 pandemic, usually require analysis in a laboratory, taking a day or more to get a result. CENOS can deliver results in around 30 minutes, enabling infected patients to be quickly isolated and treated.

CENOS can also be used for early detection of those infected but without symptoms, helping to minimize transmission and contain outbreaks. The technology is currently being piloted in veterinary settings, testing livestock for avian influenza, foot and mouth disease, Newcastle disease, and African swine fever. The KTP between Aston University and BG Research will take the company’s existing prototype and optimize its design for low-cost and high-volume manufacturing while enhancing key characteristics such as robustness, reliability, and ease of operation, assembly, and servicing.

The research will draw on expertise in the design for manufacture of medical devices from Aston University’s Engineering 4 Health (E4H) Research Centre and use the University’s advanced facilities in prototyping, materials engineering, and manufacturing processes. E4H combines research in all fields of engineering (biomedical, mechanical, chemical, electrical, and computer sciences) with health disciplines to translate innovative and emerging engineering technologies into healthcare.

The KTP will provide BG Research with a clear path towards high-volume manufacture, enabling the company to launch the CENOS instrument commercially, initially for veterinary use but, once the necessary regulations are obtained, for use in human diagnostics worldwide.

“We met with six university teams around the country, but were highly impressed with Aston University and chose them as our KTP partner,100% on merit. The University has the reach, interest, and facilities to help us get to where we need to be,” said Nelson Nazareth, managing director and chief technology officer of BG Research.

“This KTP offers us an opportunity to be involved in something with the potential to have a major impact on managing the progression of infectious diseases in countries where their burdens are most strongly felt,” added Dr. Patrick Geoghegan, senior lecturer in mechatronics and biomedical engineering and a member of the Engineering 4 Health Research Centre (E4H) at Aston University. “We hope it’s the start of a long relationship with BG Research, where we can work together to achieve their goals.”

Related Links:
Aston University
BG Research


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: USU chemists Kadin Crosby, Bamidele Filani, and Ryan Jackson have reported newly discovered functions of CRISPR-Cas12a3 (Photo courtesy of USU/M. Muffoletto)

CRISPR Discovery Paves Way for Single Diagnostic Test for COVID, Flu and RSV

Immune systems across all forms of life defend against viruses by blocking their ability to replicate. Many CRISPR-based defenses achieve this by cutting viral DNA, but these approaches can damage host... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.